<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04786782</url>
  </required_header>
  <id_info>
    <org_study_id>Yang-20210205</org_study_id>
    <nct_id>NCT04786782</nct_id>
  </id_info>
  <brief_title>The vPPG-detecting Software Guided Management of Cirrhotic Portal Hypertension</brief_title>
  <official_title>Clinical Management of Patients With Cirrhotic Portal Hypertension Based on the Noninvasive Portal Pressure Gradient (vPPG) Detecting Software, a Prospective and Controlled Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changqing Yang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Tongji Hospital, Tongji University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the possibilities and effectiveness of managing&#xD;
      cirrhotic portal hypertension using the non-invasive portal pressure gradient (PPG) detecting&#xD;
      software. In this study, the three-dimensional reconstruction and natural follow-up methods&#xD;
      have been respectively applied in the experimental (1st) and active comparator (2nd) group.&#xD;
      The virtual PPG is calculated with anatomical and hemodynamic information of portal system&#xD;
      collected by ultrasound and CT tests. Cirrhosis patients in the 1st group, with calculated&#xD;
      vPPG values, are managed with upper GI endoscopic results. Besides, patients in the 2nd&#xD;
      group, are managed according to the most updated Chinese clinical guideline for cirrhotic&#xD;
      portal hypertension, namely, patients with either liver stiffness measurement (LSM) &gt;15kPa or&#xD;
      PLT count &lt;150*10^9 should be screened and treated with upper GI endoscopy. The morbidity of&#xD;
      decompensated cirrhotic events and mortality of patients in two arms will be compared. The&#xD;
      cutoff values of vPPG to spare endoscopies with low missed VNT (varices needing treatment)&#xD;
      are preliminarily determined with the cohort data.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 3, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The morbidity of cirrhotic decompensated events</measure>
    <time_frame>2 years</time_frame>
    <description>The occurence rate of cirrhotic decompensated events of enrolled patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The mortality of cirrhosis</measure>
    <time_frame>2 years</time_frame>
    <description>Patients who die because of cirrhosis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spared endoscopies</measure>
    <time_frame>2 years</time_frame>
    <description>Patients who don't need upper endoscopic monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of missed VNT</measure>
    <time_frame>2 years</time_frame>
    <description>Missed cases of patients who have varices needing treatment</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Portal Hypertension</condition>
  <condition>Cirrhosis, Liver</condition>
  <arm_group>
    <arm_group_label>Three-dimensional reconstruction group</arm_group_label>
    <description>Portal hypertension is controlled with upper endoscopic screening and vPPG was detected by the noninvasive PPG-detecting software</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Natural follow-up group</arm_group_label>
    <description>Portal hypertension is controlled with the most updated guideline for clinical practice, namely, cirrhotic patients with either liver stiffness measurement &gt;15kPa or PLT&lt;150*10^9 should be screened with upper GI endoscopy and treated according to endoscopic results</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PPG-detecting software</intervention_name>
    <description>Virtual PPG (vPPG) of patients in experimental group is calculated based on anatomical and hemodynamic information of portal system collected by ultrasound and CT tests.</description>
    <arm_group_label>Three-dimensional reconstruction group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>LSM and PLT count</intervention_name>
    <description>Patients whose LSM &gt;15kPa, or PLT count &lt; 150*10^9 should be screened with upper GI endoscopy</description>
    <arm_group_label>Natural follow-up group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with confirmed cirrhosis by imaging tests (upper abdominal ultrasound/CT /MRI) or&#xD;
        liver biopsy pathology&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inpatients (Shanghai Tongji Hospital) with cirrhosis, which is confirmed by the imaging&#xD;
        tests (upper abdominal ultrasound/CT/MRI) or liver biopsy pathology.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Portal vein embolism;&#xD;
&#xD;
          -  2. Splenectomy;&#xD;
&#xD;
          -  3. Hepatic encephalopathy;&#xD;
&#xD;
          -  4. Hepatic space occupying lesions (such as hepatic cysts, hemangiomas, etc.) with&#xD;
             diameter &gt; 3cm and local compression effect;&#xD;
&#xD;
          -  5. Contraindications of enhanced CT test, such as iodine allergy, peripheral veins are&#xD;
             too thin to inject contrast medium;&#xD;
&#xD;
          -  6. Contraindications of upper GI endoscopy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Tongji Hospital, Tongji University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Changqing Yang, Ph.D</last_name>
      <phone>13817802801</phone>
      <email>cqyang@tongji.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Jing Li, Ph.D</last_name>
      <phone>15002116206</phone>
      <email>lijingshengping@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2021</study_first_submitted>
  <study_first_submitted_qc>March 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2021</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</investigator_affiliation>
    <investigator_full_name>Changqing Yang</investigator_full_name>
    <investigator_title>Principal Investigator,Head of Gastroenterology and Hepatology, Chief Physician, Professor</investigator_title>
  </responsible_party>
  <keyword>Virtual portal pressure gradient</keyword>
  <keyword>Enhanced upper abdominal CT</keyword>
  <keyword>Portal ultrasound</keyword>
  <keyword>Portal hypertension</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hypertension, Portal</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

